

# CURRICULUM VITAE

March 2019

**Sam Lerman, M.D.C.M., F.A.C.E.**

Citizenship: USA

Status: Married,  
Children: 3

EDUCATION

Medical - McGill University, 1971  
M.D.C.M

Pre-Medical - McGill University, 1967  
B.Sc. with distinction

## POSTGRADUATE TRAINING

1973-76 MRC of Canada Research Fellow- Department of Endocrinology & Metabolism, University of Miami School of Medicine, Miami, Fl.

1972-73 Resident I-Medicine-Jewish General Hospital

1971-72 Medical Internship - Jewish General Hospital, Montreal

## CERTIFICATION, AWARDS, LICENCES

- 1) National Boards - Parts I-III - 1971
- 2) L.M.C.C. - ( Canadian Licence) - 1972
- 3) Quebec Medical Licence- 1972, No. 172-2214
- 4) National Research Council of Canada Fellowship 1973-1976
- 5) State of Florida Medical Licence - ME 0022427

### Certifications:

- 1) American Board of Internal Medicine 1976
- 2) Specialty of Endocrinology, Quebec, 1976
- 3) American Board of Internal Medicine, Sub-specialty Endocrinology & Metabolism, 1977
- 4) Fellow American College of Endocrinology, May 1996 (F.A.C.E.)

CURRENT POSITIONS:

1. Medical Staff, Memorial Regional Hospital  
Hollywood, Florida
2. Partner, The Center for Diabetes & Endocrine Care (7/92 - present)  
Jellinger & Lerman, M.D., P. A.  
3107 Stirling Rd, Suite 300, Ft .Lauderdale, FL 33312
3. Director, Clinical Research  
The Center for Diabetes & Endocrine Care, Ft. Lauderdale, Florida

PROFESSIONAL SOCIETIES

American Association of Clinical Endocrinologists  
Florida AACE  
Endocrine Society  
American Diabetes Association

PREVIOUSLY HELD POSITIONS AND TEACHING DUTIES:

- 1) Geographic Full Time Physician
- 2) Internal Medicine and Consultant Endocrinology,  
Jewish General Hospital Montreal, Quebec 1976-1992
- 3) Assistant Clinical Professor of Medicine,  
McGill University School of Medicine Montreal, Quebec 1980 - 1992.
- 4) Director, Diabetes Self Management & Education Program,  
Jewish General Hospital Montreal, Quebec 1987 - 1992
- 5) Chairman, Mortality & Morbidity Committee, Dept. of Medicine  
Jewish General Hospital Montreal, Quebec 1987 - 1992
- 6) Member, Committee of Assessment of Medical Acts,  
Jewish General Hospital Montreal, Quebec 1987 - 1992

PREVIOUSLY HELD POSITIONS AND TEACHING DUTIES:

- 7) Treasurer, Association of Professional Endocrinologists of Quebec  
1988 - 1992
- 8) Editorial Board,  
Plein Soleil, a lay journal of the Quebec Diabetes Association  
1988 - 1992
- 9) Reviewer  
Endocrine Practice Journal  
1997
- 10) Member, Membership Committee  
American Association of Clinical Endocrinologists (AACE.)
- 11) Medical Staff, Memorial Hospital West  
Pembroke Pines, Florida
- 12) Medical Director, Diabetes Center  
Memorial Hospital West Pembroke Pines, Florida
- 13) Member, Clinical Research Committee  
American Association of Clinical Endocrinologists (AACE).
- 14) Chief, Endocrinology - Memorial Regional Hospital (07/2003 - 04/2007)  
Hollywood, Florida
- 15) Member, Editorial Advisory Board, Clinical Endocrinology News, 2007-2008

TEACHING

1986-1992

Cholesterol Awareness Program- program of education for patients  
with lipid disorders

Medical Students/House staff Teaching:

- \* Instructor/Tutor, 1st to 4th year Medical Students of McGill University  
12 week block teaching Physical Diagnosis
- \* Attending Physician, Ward Medicine-10 weeks once every 18 months
- \* Endocrine Fellow teaching/Consultation Service-Endocrinology, 3 mo/yr
- \* Endocrine Fellow teaching-Diabetic Self Management Program

TEACHING

1993-2004

- \* Undergraduate Medical Student Teaching, University of Miami  
Miami, Florida
- \* Undergraduate Medical Lecturer, Nova Southeastern University  
Davie, Florida

COMPLETED RESEARCH PROJECTS:

1. The Influence of Thyroid Hormone Deficiency on Liquid Gastric Emptying, Oral Cecal Transit, Lactose Absorption and Intolerance
2. GI symptoms in Thyroid Disease- a correlation with Dietary Habits
3. The Efficacy of Computer Assisted Blood Sugar Control in Diabetes Mellitus  
Co-investigator
4. Simvastatin vs. Lovastatin in the treatment of patients with Hypercholesterolemia  
Merck Frosst Canada -- Principal Investigator
5. Pravastatin Once Daily in Primary Hypercholesterolemia  
Squibb Pharmaceutical Canada -- Principal Investigator
6. Clinical Assessment of the B-D Pen as a Delivery System for Humulin  
Eli Lilly Canada Inc., -- Principal Investigator
7. Evaluation of Diamicon's Therapeutic Effects in Non-Insulin Dependent Diabetic Patients  
Servier Canada -- Principal Investigator
8. Fluoxetine (Lovan) vs Placebo: Long term Treatment of obese NIDDM- A Multicenter study  
Eli Lilly Canada Inc., -- Principal Investigator
9. Fluvastatin in the Treatment of Patients with Hypercholesterolemia in Clinical Practice Setting - A Multicenter Study  
Sandoz Pharmaceuticals Corp. -- Principal Investigator
10. A Randomized, Multicenter, Long-Term Follow-up Trial in Patients with Diabetic Foot Ulcers -Telios Pharmaceuticals Inc. -- Principal Investigator

COMPLETED RESEARCH PROJECTS:

11. Treatment of Infected Diabetic Foot Ulcers  
Magainin Pharmaceuticals Inc. -- Principal Investigator
12. Patients with Diabetic Gastroparesis  
Janssen Research Foundation -- Co-Investigator
13. An Insulin Sensitizer in the treatment of NIDDM Patients Requiring Insulin,  
Phase I & II  
Parke-Davis Pharmaceutical Research -- Principal Investigator
14. Protect (Precose) Study in NIDDM  
Bayer Pharmaceuticals -- Principal Investigator
15. Feminine Hygiene Study  
International Pharmaceutical Research -- Principal Investigator
16. Human X-14 Insulin Study for Type I DM  
Novo Nordisk Pharmaceuticals -- Sub-Investigator
17. IGF-I in Type I DM  
Genentech, Inc. -- Principal Investigator
18. Intravitreal Injection of Hyaluronidase in Vitreal Hemorrhage  
Advanced Corneal Systems, Inc. -- Principal Investigator
19. Type II DM with Renal Impairment using Voglibose  
Takeda America, Inc. -- Principal Investigator
20. Open-Label Pramlintide in the Treatment of Type I Diabetics  
Amylin Pharmaceuticals -- Sub-Investigator
21. Postmenopausal Women with Established Osteoporosis-Related Vertebral  
Deformities  
Proctor & Gamble -- Sub-Investigator
22. Topical Nitroglycerin Cream for the Treatment of Erectile Dysfunction  
International Medical Innovations, Inc. -- Principal Investigator

COMPLETED RESEARCH PROJECTS:

23. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel 9 Week Study of Omapatrilat in the Treatment of Mild to Moderate HTN  
Bristol-Myers Squibb -- Principal Investigator
24. A Randomized, Placebo-Controlled, Parallel-Group Study of CS-866 with Long-Term Safety Evaluation in Patients with Essential HTN  
Sankyo USA -- Principal Investigator
25. A prospective, Multicenter, Double-Blind, Parallel Design Comparative Study Evaluating Metformin Hcl vs. Glyburide in Subjects with Type II DM Controlled on Sulfonylurea Monotherapy Type II DM on sulfonylurea monotherapy  
Bristol-Myers Squibb -- Sub-Investigator
26. A Double-Blind, Randomized, Parallel-Group Study to Prospectively Evaluate the Post-Prandial Glucose Excursion, the Daytime Glucose, Safety and Tolerability of a Fixed Dose of SDZ DJN 608, A forced Titrated Dose of Glyburide and Placebo in Subjects with NIDDM on Diet Alone  
Novartis Pharmaceuticals -- Co-Investigator
27. An Open-Label, Community-Based Clinical Practice Study of Niaspan in Patients with Hyperlipidemia  
Kos Pharmaceuticals -- Principal Investigator
28. A Double-Blind, Placebo-Controlled, Multicenter, Phase III Study to Evaluate the Effects Pramlintide on Glycemic Control as Determined by Glycated Hemoglobin in Patients with in Type II DM  
Amylin Pharmaceuticals -- Principal Investigator
29. A Double-Blind, Placebo-Controlled, Multicenter, Phase III Study to Evaluate the Effects Pramlintide on Glycemic Control as Determined by Glycated Hemoglobin in Patients with in Type I DM  
Amylin Pharmaceuticals -- Principal Investigator
30. Open-Label, Long-Term Study of the Antihypertensive Activity and Safety of Omapatrilat, a Dual Metalloprotease Inhibitor, in the treatment of HTN  
Bristol-Myers Squibb -- Principal Investigator
31. REACH -- Rezulin Achieves Glycemic Control; A Multicenter, 24-week, Open-Label, Dose-Escalation Trial of Rezulin in Combination with Insulin or Sulfonylurea in Type II DM Patients, Parke-Davis -- Principal Investigator

COMPLETED RESEARCH PROJECTS:

32. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Study of the Efficacy and Safety of Metformin Hydrochloride for the Treatment of Adolescents with Type 2 Diabetes Mellitus  
Bristol-Myers Squibb -- Principal Investigator
33. Safety and Efficacy of Fixed Combination Metformin/Glyburide Products as First Line Therapy in Patients with Type II DM Who Have Inadequate Glycemic Control with Diet and Exercise  
Bristol-Myers Squibb -- Sub-Investigator
34. A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, 18 Month Study to Assess the Efficacy of Meridia 20 mg  
Knoll Pharmaceuticals -- Co-Investigator
35. Efficacy and Safety of Inhaled Compared to Subcutaneous Human Insulin in an Intensive Insulin Regimen for Subjects with Type 1 Diabetes Mellitus  
Pfizer, Inc. -- Principal Investigator
36. Efficacy and Safety of Inhaled Human Insulin Therapy in Subjects with Type 2 Diabetes Mellitus Not Well-Controlled with Combination Oral Agents  
Pfizer, Inc. -- Principal Investigator
37. Double-Blind, Placebo-Controlled, Four-Week Study of the Safety and Efficacy of CP-368,296 in Subjects with Type 2 Diabetes Mellitus  
Pfizer, Inc. -- Principal Investigator
38. The Effect of PNU-182716 on HbA1c Levels in Type 2 Diabetic Patients, a Double-Blind, Placebo-Controlled, Randomized, Multicenter Dose-Finding and Frequency Study  
Pharmacia & UpJohn -- Principal Investigator
40. A Randomized, Double-Blind, Parallel-Group Pilot Study of 3 Months Treatment with Oral GI262570 7.5 mg Once Daily, Pioglitazone 45 mg Once Daily, and Rosiglitazone 4 mg Twice Daily in Subjects with Type 2 Diabetes Mellitus  
Glaxo Wellcome, Inc. -- Principal Investigator
39. Glipizide GITS Study in a Usual Care Setting  
Pfizer, Inc. -- Principal Investigator

COMPLETED RESEARCH PROJECTS:

41. A Triple-Blind, Parallel Study to Investigate the Effect of Losartan vs. Atenolol on the Reduction of Morbidity and Mortality in Hypertensive Patients with LVH  
Merck & Company -- Principal Investigator
42. A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Renal Protective Effects of Losartan in Patients with NIDDM and Nephropathy  
Merck & Company -- Principal Investigator
43. Efficacy and Safety of Inhaled Human Insulin Therapy in Subjects with Type 2 Diabetes Mellitus not Optimally Controlled with Diet and Exercise  
Pfizer, Inc. -- Principal Investigator
44. Double-Blind, Randomized Study of the Safety and Efficacy of a Combination of Insulin and 45 mg of Actos vs. a Combination of Insulin and 30 mg of Actos in the Treatment of Type 2 Diabetes Mellitus  
Takeda America -- Principal Investigator
45. Insulin Lispro Low Mixture Plus Metformin Compared to NPH Insulin Plus Metformin in Subjects with Type 2 Diabetes Mellitus  
Eli Lilly and Company -- Principal Investigator
46. A Randomized, Double-Blind, Parallel-Group, Clinical Evaluation of GI262570 Sodium Tablets in Combination with Metformin for 26 Weeks Duration in Subjects with Type 2 Diabetes Mellitus
47. Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial with Two Parallel Groups to Measure the Efficacy of 12 Weeks Treatment with 120 mg Nateglinide vs Placebo in Treatment Naive Older Seniors with Type 2 Diabetes  
Novartis Pharmaceuticals -- Principal Investigator
48. Multicenter, Randomized, Double-Blind, Trial Comparing the Safety and Efficacy of Metformin/Glyburide to Pioglitazone in Patients with Type 2 DM  
Bristol-Myers Squibb -- Principal Investigator
49. Double-Blind, Randomized Study to Evaluate the Effects of Fixed Combination Metformin/Glipizide in Patients with Type 2 DM Who Have Inadequate Glycemic Control on Half-Maximum Doses of Sulfonylurea Monotherapy  
Bristol-Myers Squibb -- Principal Investigator



COMPLETED RESEARCH PROJECTS:

50. Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Examine the Effect on Glucose Control of AC2993 in Subjects With Type 2 DM  
Amylin Pharmaceuticals -- Principal Investigator
51. Randomized, Open Label, Crossover Trial in Insulin Requiring Diabetic Patients, Comparing the Injections with Biasp 30/MS216 Disposable Pen Device and Injections with Biasp 30/vial and Syringe  
Novo Nordisk Pharmaceuticals, Inc.
52. A Double-Blind, Randomized Comparison Study of the Safety and Efficacy of the Addition of Pioglitazone Hcl or Placebo in Reducing or Eliminating Insulin Requirement in Subjects Controlled on Insulin and Metformin Who Have Previously Failed Combination Oral Therapy  
Takeda Pharmaceuticals America -- Principal Investigator
53. A Double-Blind Randomized Comparison Study of the Long Term (2 yr) Safety and Efficacy of Pioglitazone Hcl or Glyburide in Subjects with Type 2 Diabetes Naive to Pharmacologic Therapy  
Takeda Pharmaceuticals America -- Principal Investigator
54. Randomized, Double-Blind, Parallel Study, Active Controlled Study to Evaluate the Efficacy and Safety of Treatment With Simvastatin Monotherapy Compared to Simvastatin Plus Ezetimibe in Type 2 DM Patients  
Merck and Co., Inc. – Principal Investigator
55. The Hypopituitary Control and Complications Study with Humatrope  
Eli Lilly and Company – Principal Investigator
56. Long Term Safety of Inhaled Human Insulin in Subjects with Type 1 or Type 2 DM  
Pfizer, Inc. – Principal Investigator
57. Randomized, Double-Blind, Placebo-Controlled Study of FK614 in Type 2 Diabetics  
Fujisawa Research Institute of America – Principal Investigator
58. Phase 2 Multicenter, Double-Blind, Randomized Study of the Safety and Efficacy of CP-529,414 in Subjects with Type 2 Diabetes  
Pfizer, Inc. – Principal Investigator
59. Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of Ro 205-2349 in Type 2 Diabetics  
Hoffmann LaRoche – Principal Investigator

COMPLETED RESEARCH PROJECTS:

60. Phase 2, Randomized, Double-Blind, Parallel Group Study of CRE16336 in Type 2 Diabetics

EMD Pharmaceuticals – Principal Investigator

61. Multicenter, Randomized, Open-Label, Crossover Trial in Type 1 Diabetics Comparing MS231 and Vial/Syringe/Separate Meter

Novo Nordisk Pharmaceuticals – Principal Investigator

62. Combination Therapy of Metformin with Once Daily Insulin Determir or Human Insulin NPH in Type 2 Diabetics

Novo Nordisk Pharmaceuticals – Principal Investigator

63. Comparison of Insulin Vial/Syringe with INNOLET in Elderly Subjects with Diabetes

Novo Nordisk Pharmaceuticals – Principal Investigator

64. 52 Week, Double-Blind, Parallel, Active-Controlled Study to Evaluate the Efficacy and Safety of NNC 61-0029

Novo Nordisk Pharmaceuticals – Principal Investigator

65. Double-Blind, Randomized, Parallel Group Trial to Compare the Efficacy and Safety of Metformin ER and Metformin Immediate Release in Type 2 Diabetics

DepoMed, Inc. – Principal Investigator

66. Randomized, Double-Blind, Parallel-Group Study to Assess the Effect of D-*Chiro*-Inositol on Clomiphene Citrate Induced Ovulation in Women with PCOS

Insmed Pharmaceuticals, Inc. – Sub-Investigator

67. Randomized, Double-Blind, Multicenter Study Comparing the Effects of Carvediol and Metoprolol on Glycemic Control in Hypertensive Type 2 Diabetics

GlaxoSmithKline, Inc. – Principal Investigator

68. Substituting Lantus for TZD vs. a Third Oral Agent as Add-On Therapy in Patients Failing a TZD and Sulfonylurea or TZD Metformin Combination

Aventis Pharmaceuticals – Principal Investigator

COMPLETED RESEARCH PROJECTS:

69. Open-Label, Randomized, Parallel-Group Study of the Safety and Efficacy of Nutropin Depot in Subjects with Growth Hormone Deficiency  
Genentech, Inc. – Principal Investigator
70. 18 Month, Double-Blind Phase 3 Trial with a 12-Month Interim Analysis of the Effect of Recombinant Human Parathyroid Hormone in Women with Postmenopausal Osteoporosis  
NPS Allelix Corp.. – Principal Investigator
71. Double-Blind, Randomized, Multicenter 2 Year Study of the Effect of EXO-226 on Renal Dysfunction in Diabetic Subjects  
ExoCell, Inc. – Principal Investigator
72. Advicor in the Treatment of Type 2 Diabetic Patients with Dyslipidemia Using TZD and/or Metformin  
KOS Pharmaceuticals – Principal Investigator
73. Multicenter, Double-Blind, Randomized, Dose-Ranging Study to Assess the Safety and Efficacy of LAF237 in Type 2 Diabetics  
Novartis Pharmaceuticals – Principal Investigator
74. Multicenter, Double-Blind, Randomized 6- Week Study to Evaluate the Efficacy and Safety of Ezetimibe 10 mg/day Added to Ongoing Statin vs. Statin Alone Therapy in Patient with Hypercholesterolemia  
Merck and Co. – Principal Investigator
75. Efficacy and Safety of EXUBERA Compared to Subcutaneous Insulin in Adult Type 2 Diabetics  
Pfizer, Inc. – Principal Investigator
76. Efficacy and Safety of EXUBERA Compared to Subcutaneous Insulin in Adult Type 1 Diabetics  
Pfizer, Inc. – Principal Investigator
77. Phase 2, 12-Week, Randomized, Double-Blind Study for the Safety and Efficacy of TAK-677 in Type 2 Diabetics – Open Label Extension to Follow  
Takeda Pharmaceuticals North America – Principal Investigator
78. Phase 3, Randomized, Double-Blind, Multicenter Trial to Evaluate the Safety and Efficacy of BMS-298585 in Combination with Glyburide in Patients with Type 2 Diabetes  
Bristol-Myers Squibb – Principal Investigator

COMPLETED RESEARCH PROJECTS:

79. Safety and Efficacy of Human Insulin Inhalation Powder in Patients with Type 1 Diabetes  
Eli Lilly and Co. – Principal Investigator
80. An Open Label Study to Evaluate the Safety of Lamotrigine in Subjects with Painful Diabetic Neuropathy  
GlaxoSmithKline – Principal Investigator
81. Phase 2, Randomized, Double-Blind Study to Determine the Efficacy, Safety Tolerability and Pharmacokinetics of Ro 205-2349 in Type 2 Diabetics  
Hoffmann-LaRoche, Ltd. – Principal Investigator
82. Comparison of the Effects of Teriparatide with Those of Alendronate Sodium on Lumbar Spine Bone Mineral Density in Glucocorticoid-Induced Osteoporosis  
Eli Lilly and Co. – Principal Investigator
83. Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-0767 to Patients with Type 2 Diabetes on Combined Metformin and Sulfonylurea Therapy  
Merck and Co. – Principal Investigator
84. Randomized, Double-Blind, Multicenter One Year Trial to Compare Micardis vs Cozaar in Hypertensive Type 2 Diabetic Patients with Overt Nephropathy  
Boehringer Ingelheim – Principal Investigator
85. Multicenter, Randomized, Double-Blind Clinical Evaluation of Insulin Plus Rosiglitazone Compared to insulin Plus Placebo for 24 Weeks in Type 2 Diabetics Inadequately Controlled on Insulin  
GlaxoSmithKline – Principal Investigator
86. Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GW677954 over 6 Weeks in Subjects with Type 2 Diabetes  
GlaxoSmithKline – Principal Investigator
87. Multicenter, Double-Blind, Randomized 6 Week Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin Combination vs Atorvastatin in Patients with Hypercholesterolemia  
Merck and Co. – Principal Investigator

COMPLETED RESEARCH PROJECTS:

88. Multicenter, Doubler-Blind, Randomized Study of the Safety and Efficacy of a Combination of TAK-559 and Glyburide Compared to Placebo and Glyburide in Type 2 Diabetics  
Takeda Pharmaceuticals North America – Principal Investigator
89. Multicenter, Doubler-Blind, Randomized Study of the Safety and Efficacy of a Combination of TAK-559 and Glyburide Compared to Placebo in Type 2 Diabetics  
Takeda Pharmaceuticals North America
90. Phase 3, Randomized, Double-Blin, Multicenter Study to Evaluate the Safety and Efficacy of BMS-298585 in Combination with Metformin Compared to Pioglitazone in Combination with Metformin in Type 2 Diabetics  
Bristol-Myers Squibb – Principal Investigator

PUBLICATIONS

1. Perinatal Primate Parathyroid Hormone Metabolism, A.R. Fleischman, S. Lerman, G.K. Oakes, M.F. Epstein, R.A. Chez, D. H. Mintz, Bio. Neonate, 27: 40-49, 1975.
2. Parathyroid Hormone and the Hypercalcemia of Immobilization, S. Lerman, J.M. Canterbury, Eric Reiss, J.C.E.M., 45: 425, Sept. 1977.
3. Vitamin D., Metabolites and Parathyroid Hormone Secretions, Canterbury J.M., S. Lerman, Clafin, A.J., Reiss, E., Henry, H.L., Norman, A.W., J. of Clinical Investigation,: 1375-1383, May 1978.
4. Hyperthyroidism and Polycythemia Vera with Chronic Urticaria and Angioedema, Small, P., and Lerman, S., Annals of Allergy, 46: 256-259, May 1981.
5. Ethanol, Thyroid Hormones and Acute Liver Injury: Is there a Relationship?, A. Szilagyi, S. Lerman, R.H. Resnick, Hepatology, 3:593-600, 1983.
6. Human Insulin Allergy, P. Small and S. Lerman, Annals of Allergy, 53: 39-41, July 1984.

## PUBLICATIONS

7. Tetracycline Instillation for Recurrent Cystic Thyroid Nodules, J.P. Deyoung, A. Kahn, S. Lerman, A.S. Ferency, The Canadian Journal of Surgery, 29:2: 118-118-119, March 1986.
8. Parathyroid Cyst: Diagnosis and Treatment of An Unusual Surgical Problem, B. Mitmaker, S. Lerman, S.R. Lamoureux, L. Begin, The Canadian Journal of Surgery, 34:1, 59-61, Feb 1991.
9. Reversible lactose malabsorption and intolerance in Graves' Disease, S.Szilagy, S.Lerman, R.G. Barr, et al, Clin Invest Med 14:3, 188-197, 1991.
10. Comparison of the short term efficacy and tolerability of Lovastatin and Simvastatin in the Management of Primary Hypercholesterolemia, J.Frohlich and Canadian lovastatin/simvastatin Study Group, Can J Cardiol 9:5, 405-412, June 1993.
11. Efficacy of Inhaled Insulin in Patients with Type 2 Diabetes not Controlled with Diet and Exercise. DeFronzo R.A., Bergenstal R.M., Cefalu W.T., J.Pullman, Lerman S., Bode B., Phillips L.S., Diabetes Care 28:1922-1928, 2005.

## ABSTRACTS

1. The Effects of Vitamin D Metabolites on PTH Secretion, Canterbury, J.M., Lerman, S., Claflin, A.J., Reiss, E., Henry, H.L., Norman, A.W., Presented at 6th Parathyroid Conference, Vancouver, June 1977.
2. The Role of Parathyroid Hormone in Fetal and Neonatal Calcium Homeostasis, Lerman, S., Fleischman, Oakes, G.K., Epstein, M.F., Chez, R.A., Mintz, D.H. Clinical Research, Vol. 22: 3: 474A, April 1974, page 3 Presented May 4, 1974, 31st Annual Meeting of the American Federation for Clinical Research, Atlantic City, New Jersey.
3. In Vivo Effects of Vitamin D Metabolites on Parathyroid Hormone (PTH) Secretion, Canterbury, J.M., Claflin, A.J., Lerman, S., Henry, H.L., Norman, A.W., Reiss, E., Endocrinology, Vol 98, Abstract 17, 1976. Presented at 58th Annual Meeting of the Endocrine Society, San Francisco, 1976.

ABSTRACTS

4. Elevated Serum Parathyroid Hormone Concentrations in Hyperthyroidism, Lerman, S., Vesely, D.L., Weinstein, R.S., Canterbury, J.M., Levy, G.S. Presented at American Thyroid Association Meeting, Toronto, Canada, September 1976.
5. Selection of Parathyroid Hormone Antisera for Pre-operative Localization Studies, Reiss, E., Lerman, S., Canterbury, J.M., Clinical Research, Vol 24: 487A, 1976.
6. Combined Protein Sparing Modified Fasting and Behaviour Modification as an Approach to Weight Reduction, Granich, A., Lerman, S., Rosberger, Z., Dyne, J. Presented by A. Granich at the 6th World Congress of the International College of Psychosomatic Medicine, September 1981.
7. Naloxone Protects Gastric Mucosa from Acute Erosions in the Spinal Rat (Abstract), Gastroenterology, H.H. Sigman, A. Gillich and S. Lerman, 1983.
8. The Long Term Outcome of Combined Protein Sparing Modified Fasting and Behaviour Modification for Weight Reduction, Z. Rosberger, S. Lerman, B. Mills. Presented at the IV International Congress on Obesity, October 1983.
9. Lactose Intolerance in Thyroid Disease. A. Szilagyi, S. Lerman. Presented at Royal College Meetings, Edmonton, September 1989.
10. A Pilot Study Of Efficacy Of Computer Assisted Blood Sugar (BS) Control In Insulin Requiring Diabetes Mellitus. M. Baron and S. Lerman. Presented at the American Diabetes Association, Poster Session June 18, 1992.
11. Canadian Multicenter Study Comparing Lovastatin (L) with Simvastatin (S) in the Treatment of Primary Hypercholesterolemia. J. Frohlich and Canadian Lovastatin/Simvastatin Study Group. Presented at the XI International Conference on Drug
12. Open -label Phase 2 Study To Assess Safety and Efficacy of Relacorilant (Cort 125134), A Selective Cortisol Modulator In The Treatment of Endogenous Hypercortisolism. Margaret E. Wierman, Nidhi Agrawal, Irina Bancos, Francesco S. Celi, Murray Gordon, Atil Y. Kargi, Sam Lerman, Cary Mariash, Julie M. Silverstein and Andreas G. Moraitis  
  
Presented at the 27<sup>th</sup> Annual Scientific & Clinical Congress, American Association of Clinical Endocrinologists, May 16-20, 2018.